Compare FTCI & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | BDSX |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 122.0M |
| IPO Year | 2021 | 2020 |
| Metric | FTCI | BDSX |
|---|---|---|
| Price | $4.53 | $15.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $10.80 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 146.0K | 136.0K |
| Earning Date | 03-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $47,355,000.00 | ★ $88,499,000.00 |
| Revenue This Year | $89.54 | $23.35 |
| Revenue Next Year | $36.35 | $19.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $2.13 | $0.25 |
| 52 Week High | $12.75 | $20.21 |
| Indicator | FTCI | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 32.42 | 48.82 |
| Support Level | $4.07 | $6.33 |
| Resistance Level | $5.20 | $20.21 |
| Average True Range (ATR) | 0.54 | 1.72 |
| MACD | 0.05 | -0.46 |
| Stochastic Oscillator | 13.30 | 7.77 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.